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Abstract
Background: This study was to systematically test whether previously reported risk fac-
tors for chronic kidney disease (CKD) are causally related to CKD in European and East
Asian ancestries using Mendelian randomization.
Methods: A total of 45 risk factors with genetic data in European ancestry and 17 risk factors
in East Asian participants were identified as exposures from PubMed. We defined the CKD
by clinical diagnosis or by estimated glomerular filtration rate of <60 ml/min/1.73 m2.
Ultimately, 51 672 CKD cases and 958 102 controls of European ancestry from CKDGen, UK
Biobank and HUNT, and 13 093 CKD cases and 238 118 controls of East Asian ancestry from
Biobank Japan, China Kadoorie Biobank and Japan-Kidney-Biobank/ToMMo were included.
Results: Eight risk factors showed reliable evidence of causal effects on CKD in Europeans,
including genetically predicted body mass index (BMI), hypertension, systolic blood pres-
sure, high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein(a), type 2 diabe-
tes (T2D) and nephrolithiasis. In East Asians, BMI, T2D and nephrolithiasis showed evi-
dence of causality on CKD. In two independent replication analyses, we observed that
increased hypertension risk showed reliable evidence of a causal effect on increasing CKD
risk in Europeans but in contrast showed a null effect in East Asians. Although liability to
T2D showed consistent effects on CKD, the effects of glycaemic phenotypes on CKD were
weak. Non-linear Mendelian randomization indicated a threshold relationship between ge-
netically predicted BMI and CKD, with increased risk at BMI of >25 kg/m2.
Conclusions: Eight cardiometabolic risk factors showed causal effects on CKD in
Europeans and three of them showed causality in East Asians, providing insights into the
design of future interventions to reduce the burden of CKD.
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Introduction
Chronic kidney disease (CKD) affects 10–15% of the popu-
lation worldwide. It has a major effect on global health,
both as a direct cause of morbidity and mortality, and as an
important complication for cardiometabolic diseases.1–3
From 1990 to 2017, the global age-standardized mortality
for many important non-communicable diseases has de-
clined. For example, cardiovascular disease mortality has
been reduced by 30.4%. However, the mortality decline for
CKD has been just 2.8%.4 The majority of interventional
trials have focused on disease treatment rather than primary
prevention. In the literature, impaired fasting glucose, high
blood pressure and high body mass index (BMI) are among
the leading risk factors for CKD. However, even with exist-
ing interventions for these risk factors, the burden of CKD
has not declined as expected.4 Moreover, CKD awareness is
limited among the general public and healthcare authorities.
Thus, a systematic assessment of the causal determinants of
CKD is urgently needed to promote a shift from the treat-
ment of CKD patients to the prevention of the disease in
high-risk groups.
Well-designed randomized–controlled trials (RCTs) are
usually the best approach to estimate a causal relationship
between a risk factor and a disease. Whereas several studies
have identified risk factors for CKD progression, there is a
lack of reliable evidence to support their causal roles on
CKD incidence. Mendelian randomization (MR) is an epide-
miological method that can be used to obtain evidence
about the causal effects of modifying intervention targets.5
MR exploits the random allocation of genetic variants at
conception and is therefore less susceptible to confounding
and reverse causality than traditional observational studies.
The increasing availability of genetic-association resources
provides a timely opportunity to test the causal effects of
various risk factors on CKD.6,7
In this study, we aimed to investigate the causal effects
of 45 previously reported risk factors on CKD using two-
sample linear and non-linear MR approaches. We used
the largest available genome-wide association studies
(GWASs) for risk factors in European and East Asian
ancestries. Summary data for CKD and estimated glomer-
ular filtration rate (eGFR) were obtained from >1 million
participants from the CKDGen consortium,8 UK
Biobank,9 Trøndelag Health (HUNT) Study,10 Biobank
Japan,11 China Kadoorie Biobank12 and Japan-Kidney-
Biobank/ToMMo consortium.
Methods
The data, analytic methods and study materials will be
made available to other researchers for purposes of repro-
ducing the results. For more details, the genetic-association
data of the selected risk factors are available in
Supplementary Tables (available as Supplementary data at
IJE online). The GWAS summary statistics for CKD and
eGFR that were generated using UK Biobank and
CKDGen data are available from the MRC-IEU
OpenGWAS database (https://gwas.mrcieu.ac.uk/) and
CKDGen website (http://ckdgen.imbi.uni-freiburg.de/) re-
spectively. The GWAS results from HUNT, Biobank
Japan, China Kadoorie Biobank and Japan-Kidney-
Biobank/ToMMo can be accessed by request to the data
holders. The analytical script of the MR analysis con-
ducted in this study is available via the GitHub repository
of the ‘TwoSampleMR’ R package (https://github.com/
MRCIEU/TwoSampleMR/).
Key Messages
• This large-scale genetic study found robust evidence to support the causal roles of eight cardiometabolic risk factors
on chronic kidney disease (CKD) among Europeans and three of these risk factors were causal among East Asians.
• Trans-ethnic comparison suggested that hypertension showed a strong causal role on CKD in Europeans but no
substantial role in East Asians.
• The genetic evidence suggested that type 2 diabetes may have glucose-independent mechanisms to influence CKD.
• This study highlighted importance of controlling the multimorbidity of cardiovascular disease and CKD as an
intervention strategy to reduce the burden of both diseases.
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Study design
Our study consisted of four components (Figure 1). First, we
identified 45 risk factors for CKD by mining PubMed.
Second, we estimated the causal effects of these risk factors
on CKD and eGFR in CKDGen,8 UK Biobank,9 HUNT
Study,10 Biobank Japan,11 China Kadoorie Biobank12 and
Japan-Kidney-Biobank/ToMMo consortium separately.
Third, we evaluated the findings based on the strength and
consistency of the evidence across MR methods and across in-
dividual studies. Finally, we conducted extensive follow-up
Figure 1 Study design of the trans-ethnic Mendelian-randomization study of chronic kidney disease
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
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analyses to confirm the findings for blood pressure, glycaemic
and blood lipid phenotypes on CKD. Finally, non-linear MR
was performed to estimate the optimal BMI and fasting glu-
cose levels for reducing CKD risk in UK Biobank and the
HUNT Study.
Selection of risk factors
CKD risk factors were identified from a literature review
using MELODI-Presto13,14 to search the PubMed database
(Supplementary Note S1, available as Supplementary data
at IJE online). We identified 45 risk factors for CKD, in-
cluding blood-pressure phenotypes, glycaemic phenotypes,
lipid phenotypes, obesity, smoking, alcohol intake, sleep
disorders, nephrolithiasis, serum uric acid, coronary artery
disease, bone mineral density, homocysteine, C-reactive
protein, micro-nutrient phenotypes (serum metals and vita-
mins), dehydration and thyroid phenotypes. By searching
the largest available GWASs (ensuring minimum sample
overlap with the outcome samples), we extracted genetic
variants associated with all 45 risk factors from European
ancestry studies and extracted 17 of the 45 risk factors
from East Asian ancestry studies (Supplementary Table S1
and Supplementary Note S1, available as Supplementary
data at IJE online). To select the independent genetic var-
iants, the genome-wide significant single-nucleotide poly-
morphism (SNPs) were grouped by linkage disequilibrium
(LD) (r2<0.001 for SNPs within 1 Mb genomic region)
and the SNP with the lowest P-value per group was
retained (Supplementary Tables S2 and S3, available as
Supplementary data at IJE online).
Association of genetic variants with CKD and
eGFR
In UK Biobank,9 HUNT Study10 and China Kadoorie
Biobank,12 CKD was defined according to the
International Classification of Diseases (ICD) 10th
Revision. The CKD cases were defined as participants
with ICD 10 code N18. The participants with any type of
kidney conditions (N00 to N29) were excluded from the
controls to reduce the possibility of including CKD cases
in the control group. In Japan-Kidney-Biobank/ToMMo
consortium, CKD was defined as eGFR of <60 ml/min/
1.73 m2 and/or the presence of urine abnormality, which
is similar to the clinical diagnosis for CKD. In CKDGen8
and Biobank Japan,11 CKD was defined as eGFR of
<60 ml/min/1.73 m2. In all studies, eGFR was estimated
from serum creatinine using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) formula.15 The
genetic associations with CKD and eGFR were reported
in three studies of European ancestry (CKDGen: 41 395
cases, 439 303 controls, 8.7% diabetes patients; UK
Biobank: 6985 cases, 454 323 controls, 5.2% with diabe-
tes; and HUNT Study: 3292 cases, 64 476 controls, 4.9%
with diabetes). The genetic associations with CKD were
reported in three East Asian studies (Biobank Japan: 8586
cases, 133 808 controls, 10.2% with diabetes; China
Kadoorie Biobank: 461 cases, 94 887 controls, 6.7%
with diabetes; Japan-Kidney-Biobank/ToMMo consor-
tium: 4046 cases, 9423 controls, 7.3% with diabetes) and
eGFR genetic associations were reported in Biobank
Japan (Supplementary Table S4 and Supplementary Note
S2, available as Supplementary data at IJE online). All
participants included in the CKDGen,8 UK Biobank,9
HUNT,10 Biobank Japan,11 China Kadoorie Biobank12
and Japan-Kidney-Biobank/ToMMo provided written in-
formed consent and studies were approved by their local
research ethics committees and institutional review
boards as applicable.
Statistical analysis
MR is an instrumental variable method that uses genetic
variants as instruments to test the causal relationships be-
tween an exposure (e.g. BMI) and an outcome (e.g. CKD)
and requires three core assumptions to be satisfied
(Supplementary Figure S1 and Supplementary Note S3,
available as Supplementary data at IJE online). For binary
exposures [e.g. type 2 diabetes (T2D)], we converted the
odds ratios (ORs) [multiplying log(ORs) by log (2) (equal
to 0.693) and then exponentiating] in order to represent
the OR of outcome per doubling of the odds of susceptibil-
ity to the exposure.16,17
The MR estimates for each risk factor were determined
using inverse variance weighted (MR-IVW) analysis, which
uses the random-effects meta-analysis approach to com-
bine the Wald ratio estimates18 of the causal effect
obtained from each of the tested SNPs. A set of sensitivity
analyses, including MR–Egger,19 MR weighted median,20
MR mode estimator21 and a heterogeneity test,22 were
conducted to test the underlying MR assumptions. We also
examined the possibility of reverse causality using bidirec-
tional MR23 and applied multivariable MR analyses of the
correlated phenotypes (Supplementary Note S4, available
as Supplementary data at IJE online). A conservative
Bonferroni-corrected threshold (a¼ 1.11 10–3, as 45 risk
factors were assessed) was used to account for multiple
testing. Supplementary Note S5 (available as
Supplementary data at IJE online) demonstrates the instru-
ment strength estimation20 and power calculations.24,25
The MR and sensitivity analyses were conducted using the
TwoSampleMR package.26
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Follow-up MR analyses
To validate the different causal pattern of blood pressure
across ancestries, we conducted a set of follow-up analyses:
(i) to estimate the potential influence of instrument size and
resulting power of the MR analyses, we conducted novel
East Asian GWASs of hypertension (N cases¼ 40 318, N
controls¼60 323), systolic blood pressure (SBP), diastolic
blood pressure (DBP) and pulse pressure (PP) in 100 641
China Kadoorie Biobank participants. By extract genetic
instruments from the well-powered GWASs, we further in-
creased the instrument strength (F-statistics) of hypertension
from 275.19 to 330.85 (Supplementary Table S3, available
as Supplementary data at IJE online). Using these data as
instruments, we conducted a validation MR between the
blood-pressure phenotypes and CKD in the three East Asian
studies; (ii) for the European SBP and DBP instruments, we
checked whether their genetic associations were replicated
in the East Asian GWASs.27 We then used the replicated
SNPs of SBP and DBP (Supplementary Table S5, available
as Supplementary data at IJE online) to conduct a second
validation MR (noted as European variant þ East Asian ef-
fect analysis); (iii) we compared the direction of effect and
the heterogeneity of the genetic effects of hypertension in
Europeans and East Asians using pair-wise Z test and ran
sensitivity MR analysis to remove instruments with
heterogeneity.
To better understand the causal mechanisms linking
T2D with CKD, four additional MR analyses were con-
ducted: (i) we validated the effects of eight glycaemic phe-
notypes on CKD using Steiger filtering28 and radial MR;29
(ii) we considered the influence of the genetic liability for
type 1 diabetes (T1D)30 (Supplementary Table S2, avail-
able as Supplementary data at IJE online) on CKD; (iii)
participants with eGFR measurements were stratified into
diabetic (N¼11 529) and non-diabetic populations
(N¼ 118 460)31 and we conducted MR analyses of T2D
and five glycaemic phenotypes on eGFR in these two sub-
populations; (iv) diabetic retinopathy was included as a
positive control outcome to validate the analytical ap-
proach. The instruments for T2D and glycaemic pheno-
types were used as exposures, whereas the CKD data from
CKDGen, UK Biobank and HUNT as well as the diabetic
retinopathy data from UK Biobank SAIGE release32 were
used as outcomes (Supplementary Table S4, available as
Supplementary data at IJE online).
To validate the MR findings of lipids on CKD, the follow-
ing analyses were conducted: (i) to validate the high-density
lipoprotein cholesterol (HDL-C) MR results in East Asians,
we conducted the same European variant þ East Asian effect
analysis to boost the power of the MR findings (HDL-C data
from Spracklen et al.33) (Supplementary Table S5, available
as Supplementary data at IJE online); (ii) we tested the inde-
pendent effect of HDL-C and apolipoprotein A-I on CKD
using a multivariable MR model (Supplementary Note
S4, available as Supplementary data at IJE online); (iii)
we estimated the effect of circulating cholesteryl ester
transfer protein levels34 on CKD (Supplementary Table
S2, available as Supplementary data at IJE online); (iv)
given that lipoprotein(a) levels for a fixed apolipopro-
tein(a) isoform size may vary, we estimated the effect of
apolipoprotein(a) isoform size on CKD [lipoprotein(a)
KIV2 repeats and apolipoprotein(a) protein isoform size
data from Saleheen et al.35] (Supplementary Table S2,
available as Supplementary data at IJE online).
Finally, for BMI and fasting glucose, a fractional poly-
nomial approach36–38 was applied to estimate the non-
linear shape of the association between these risk factors
and CKD using data from UK Biobank and HUNT
(Supplementary Note S6, available as Supplementary data
at IJE online).
Evaluation of MR evidence
Previous studies have suggested that P-value thresholds
should not be the only criteria to define ‘signifi-
cance’.39,40,41 We therefore evaluated the MR evidence us-
ing three criteria: (i) MR evidence strength: whether the
MR-IVW estimate of each risk factor passed the
Bonferroni-corrected P-value threshold (P< 1.1 10–3) in
at least one study and passed the replication threshold
(P< 0.05) in at least one other study; (ii) fit of MR
assumptions: whether the MR estimates for each risk fac-
tor showed the same direction of effect across MR sensitiv-
ity analyses and showed limited influence of horizontal
pleiotropy using the MR–Egger intercept term and hetero-
geneity test; (iii) whether the direction of the MR effect of
each risk factor on CKD was consistent across multiple
studies. Figure 1 demonstrates how the MR evidence was
evaluated in Europeans and East Asians separately:
‘Reliable evidence’ refers to risk factors that fulfilled all the
three criteria, whereas ‘Weak evidence’ refers to risk fac-
tors that do not fulfil all the criteria (e.g. MR estimates
with strong MR evidence but with inconsistent
directionality).
Results
Causal effects of risk factors on CKD
Most of the 45 risk factors had strong genetic instruments for
both ancestries (F-statistics>10 for 44 of the 45 risk factors
in Europeans and 15 of the 17 risk factors in East Asians;
Supplementary Tables S2 and S3, available as Supplementary
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data at IJE online). However, instruments tended to be stron-
ger in Europeans compared with East Asians (Supplementary
Table S6, available as Supplementary data at IJE online).
Effect estimates for the 45 risk factors on CKD in Europeans
and 17 risk factors in East Asians are presented in Figure 2.
Effect estimates for the other sensitivity analyses can be found
in Supplementary Tables S7–S12 (available as Supplementary
data at IJE online). Detailed evaluations of the causal evi-
dence in Europeans and East Asians are presented in
Supplementary Tables S13A and S13B (available as
Supplementary data at IJE online).
Risk factors showing reliable MR evidence
In European ancestry, eight risk factors were associated with
CKD. The OR [95% confidence intervals (CIs)] for CKD per
1-SD increase in continuous risk factors was 1.78 (1.64 to
1.94) for BMI, 1.24 (1.12 to 1.37) for SBP, 1.13 (1.07 to
1.19) for lipoprotein(a) levels, 0.93 (0.90 to 0.97) for HDL-C
and 0.96 (0.94 to 0.98) for apolipoprotein A-I. The OR
(95% CI) per doubling in the odds of genetic liability for the
binary risk factors was 2.05 (1.59 to 2.64) for hypertension,
1.20 (1.09 to 1.31) for nephrolithiasis and 1.08 (1.05 to
1.12) for T2D. The effects of these eight risk factors on CKD
were consistent across UK Biobank, CKDGen and HUNT
(Supplementary Figure S2A and Supplementary Tables S7A,
S8A and S9A, available as Supplementary data at IJE online).
In East Asian participants, genetically predicted higher
BMI (OR¼ 1.42, 95% CI¼ 1.20 to 1.69, P¼ 6.4910–5),
increased nephrolithiasis risk (OR¼ 1.12, 95% CI¼1.04
to 1.19, P¼ 1.11 10–3) and increased T2D risk
(OR¼ 1.07, 95% CI¼ 1.03 to 1.10, P¼ 1.66 10–4) were
all associated with increased risk of CKD (Supplementary
Figure S2B, available as Supplementary data at IJE online).
The effect of T2D on CKD was consistent across the three
East Asian studies. However, the effect of BMI and neph-
rolithiasis on CKD was not observed in the China
Kadoorie Biobank—this is likely due to the limited number
of CKD cases in this resource (Supplementary Tables
S10A–S12, available as Supplementary data at IJE online).
Figure 2 Forest plot for causal effects of the 45 risk factors on chronic kidney disease in Europeans and the 17 risk factors on chronic kidney disease in
Eastern Asians. (A) Causal estimates using European data; (B) causal estimates using Eastern Asian data. For binary exposures, the effect reported
on the x-axis is the odds ratio of chronic kidney disease per doubling in the odds of the exposure. For continuous exposure, the effect on the x-axis is
the odds ratio of chronic kidney disease per 1 standard deviation change in the exposure. CKD, chronic kidney disease.
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We also conducted several sensitivity analyses. The bidi-
rectional MR analysis found a consistent effect of in-
creased CKD risk on increasing hypertension risk in
European ancestry (Supplementary Table S14, available as
Supplementary data at IJE online). The multivariable MR
results for T2D, BMI and hypertension on CKD are in-
cluded in Supplementary Table S15A–C, available as
Supplementary data at IJE online. The MR analyses using
eGFR as an outcome showed similar results to those for
CKD (Supplementary Tables S7B–S10B, available as
Supplementary data at IJE online).
Risk factors showing weak MR evidence
There was weak evidence to support a causal effect on CKD
of the remaining 37 risk factors considered in the European
ancestry analyses (Supplementary Tables S7–S9, available as
Supplementary data at IJE online) and 14 risk factors consid-
ered in the East Asian ancestry analyses (Supplementary
Tables S10–S12, available as Supplementary data at IJE on-
line). Some established risk factors, such as smoking and se-
rum uric acid, were among those with weak evidence. In
addition, shorter sleep duration showed evidence to support
an association with CKD in Japan-Kidney-Biobank/ToMMo
(Supplementary Table S11, available as Supplementary data
at IJE online) and in UK Biobank (Supplementary Table S7A,
available as Supplementary data at IJE online), which was
not replicated in other studies.
Follow-up MR analyses of key findings
Effect of blood-pressure phenotypes on CKD across
populations
Figure 3 demonstrates that blood-pressure phenotypes, in-
cluding genetic liability of hypertension and genetically
predicted SBP and PP, showed strong causal effects on
CKD in the European studies but appeared to show a null
causal effect in the corresponding East Asian studies (ORs
for liability of hypertension on CKD ranging from 1.46 to
1.77 in Europeans but only from 0.99 to 1.07 in East
Asians). To validate these MR results, we first checked the
strength of genetic instruments for the four blood-pressure
phenotypes and observed that the instrument strengths
were substantially above the F-statistics threshold of 10 for
all four phenotypes in Europeans and East Asians
(Supplementary Table S6, available as Supplementary data
at IJE online). To further boost power, we used genetic
instruments for hypertension, SBP, DBP and PP from
100 641 China Kadoorie Biobank participants [which
Figure 3 Forest plot for causal effects of four blood-pressure phenotypes on chronic kidney disease risk. The subplots represent Mendelian-randomi-
zation results of different blood-pressure phenotypes. CKD, chronic kidney disease.
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obtained better instrument strength than the European hy-
pertension data (F-statistics¼ 61.11 in Europeans vs 330.85
in East Asians); Supplementary Tables S2 and S3, available
as Supplementary data at IJE online] and still observed null
results in East Asians (Supplementary Table S16A, available
as Supplementary data at IJE online). Third, we conducted
an MR analysis using the European SBP and DBP instru-
ments extracted from the East Asian studies (Supplementary
Table S5, available as Supplementary data at IJE online),
which showed similar null results (Supplementary Table
S16B, available as Supplementary data at IJE online).
Finally, we estimated the heterogeneity of genetic effects of
hypertension across Europeans and East Asians and ob-
served that 20.9% of the instruments showed distinguished
effects across the two ancestries (Supplementary Table S17,
available as Supplementary data at IJE online). Sensitivity
MR analyses excluding the heterogenous instruments, con-
trolling for different genetic architectures of BP across ances-
tries, showed similar MR results (Supplementary Table S18,
available as Supplementary data at IJE online). These analy-
ses provide additional evidence that blood pressure has a
population-specific role in CKD aetiology.
Effects of glycaemic phenotypes and CKD
Although the evidence for an effect of T2D on CKD was reli-
able, we detected little evidence to support the effects of eight
glycaemic phenotypes [fasting insulin (FI), fasting glucose
(FG), 2-hour glucose (2hGlu), fasting proinsulin (FP), hae-
moglobin A1c (HbA1c), HOMA-B, insulin-like growth fac-
tor binding protein 3 and insulin-like growth factor I] on
CKD (Supplementary Figure S3, available as Supplementary
data at IJE online) and eGFR (Supplementary Figure S4,
available as Supplementary data at IJE online). Follow-up
analyses showed that: (i) similar results were observed after
controlling for possible reverse causation of instruments and
potential outliers (Supplementary Table S19A, available as
Supplementary data at IJE online); (ii) little evidence was
observed that genetic liability to T1D was associated
with CKD risk in any of the three outcome studies from
European ancestry (Supplementary Table S19B, available as
Supplementary data at IJE online), which further supported
the weak effect of glucose on CKD; (iii) for the MR analysis
using stratified eGFR in Europeans, little effect of glycaemic
phenotypes on eGFR was observed in both diabetic and non-
diabetic samples (Supplementary Table S19C, available as
Supplementary data at IJE online), which suggested that the
weak effect of glucose on CKD could be independent of dia-
betes; (iv) fasting glucose and genetic liability to T2D were
associated with diabetic retinopathy (Supplementary Table
S19D, available as Supplementary data at IJE online), sug-
gesting that the genetic predictors of glycaemic phenotypes
used for the main MR analyses were reliable.
Effects of blood lipids and CKD
For the MR findings of lipids, our follow-up analyses
showed a few novel observations. First, we observed differ-
ent MR evidence for genetically predicted HDL-C on CKD
across Europeans and East Asians. In Europeans, good MR
evidence was observed to support the effects of HDL-C and
apolipoprotein A-I on CKD (Supplementary Tables S7–S9,
available as Supplementary data at IJE online), whereas
there was weaker MR evidence for the effect of HDL-C on
CKD in East Asians (Supplementary Tables S10–S12, avail-
able as Supplementary data at IJE online). To test the poten-
tial influence of the power of the HDL-C effect on CKD in
East Asians (OR¼ 0.94, 95% CI¼0.87 to 1.02), we con-
ducted MR using better-powered European HDL-C instru-
ments extracted from the East Asian studies (Supplementary
Table S5, available as Supplementary data at IJE online).
Using this approach, we found reliable MR evidence
(OR¼ 0.89, 95% CI¼ 0.83 to 0.96; Supplementary Table
S16C, available as Supplementary data at IJE online). This
suggests that HDL-C may have an effect on CKD in both
populations. Second, using European data, a multivariable
MR considering both HDL-C and apolipoprotein A-I in the
same model was conducted. This showed that the effect of
HDL-C on CKD was independent of apolipoprotein A-I
(Supplementary Table S15D, available as Supplementary
data at IJE online). Third, following the HDL-C finding,
we found an effect of the circulating cholesteryl ester
transfer protein level on CKD in CKDGen (OR¼ 1.06,
95% CI¼ 1.01 to 1.11, P¼ 0.01; Supplementary Table S20,
available as Supplementary data at IJE online). Finally, we
investigated the potential influence of the apolipoprotein(a)
size on CKD but found little evidence for a causal effect.
This suggests that the effect of the lipoprotein(a) level on
CKD may be independent of the apolipoprotein(a) size
(Supplementary Table S21, available as Supplementary data
at IJE online).
Non-linear effects of BMI and fasting glucose on CKD
We observed a threshold relationship between genetically pre-
dicted BMI and CKD (Supplementary Table S22, available as
Supplementary data at IJE online). The curved shape of this
relationship suggests a higher risk of CKD in overweight or
obese participants, with the optimal BMI threshold at
25 kg/m2 in both UK Biobank and HUNT (Figure 4).
Stratified analyses split by sex (Supplementary Figure S5,
available as Supplementary data at IJE online) and age
(Supplementary Figure S6, available as Supplementary data
at IJE online) suggested similar effects for genetically pre-
dicted BMI on CKD. Genetically predicted fasting glucose
showed weak evidence for a non-linear relationship with
CKD (Supplementary Figure S7 and Supplementary Table
S22, available as Supplementary data at IJE online). This
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finding was consistent both among males and females
(Supplementary Figure S8, available as Supplementary data
at IJE online) and different age groups (Supplementary Figure
S9, available as Supplementary data at IJE online).
As a summary, we systematically compared the MR
findings with existing clinical evidence in KDIGO guide-
lines and listed the potential clinical implications in
Table 1.
Discussion
In this trans-ethnic MR study, we comprehensively
assessed the causality of 45 risk factors on CKD and eGFR
in >1 million Europeans and 17 risk factors on CKD and
eGFR in >250 000 East Asians. Using MR approaches, in-
cluding five two-sample MR methods and multivariable
MR, we found reliable evidence for the causal effects of
eight cardiometabolic-related risk factors [BMI, SBP, hy-
pertension, T2D, nephrolithiasis, HDL-C, apolipoprotein
A-I and lipoprotein(a)] on CKD. The remaining 37 risk
factors, including smoking and serum uric acid, had weak
evidence to support causal effects on CKD using the cur-
rently available data. These findings are consistent with
previous MR studies that analysed similar risk factors sep-
arately.40–44 In addition, the null finding of the serum uric
acid agreed with the recent clinical trial investigating the
effects of serum urate lowering (using Allopurinol) on
CKD progression.45,46 Notably, our extensive MR and
follow-up analyses suggested the possibility of glucose-
independent pathways linking T2D with CKD. Using non-
linear MR, we observed a threshold relationship between
genetically predicted BMI and CKD risk, with increased
CKD risk at a BMI of >25 kg/m2.
The causal patterns of 17 risk factors were compared
across the two ancestries and we observed consistent
effects of T2D, BMI and nephrolithiasis on CKD in
Europeans and East Asians. In contrast, distinguishable
causal patterns between ancestries were observed when ex-
amining the effect of hypertension on CKD, with a strong
causal estimate in Europeans that was not replicated in the
analysis of East Asians. These findings indicate that careful
consideration is needed before implementing interventions
for CKD risk factors in participants of one ancestry based
on the evidence from another ancestry.
Among the prioritized risk factors, hypertension is one
of the most common risk factors for kidney-function de-
cline in patients with or without CKD.47–49 A recent bidi-
rectional MR study in Europeans supported the causal
effects of higher kidney function on lower blood pressure
using eGFR instruments controlled by blood urea nitrogen.
However, the same study suggested inconclusive evidence
of an effect of blood pressure on eGFR.50 In our MR analy-
sis, we found evidence of positive bidirectional causal
effects between hypertension and CKD in Europeans.
Figure 4 Non-linear Mendelian randomization of body mass index on chronic kidney disease risk. The dose–response curve between body mass in-
dex and chronic kidney disease risk for (A) UK Biobank and (B) the HUNT Study. The gradient at each point of the curve is the localized average causal
effect. Shaded areas represent 95% confidence intervals. CKD, chronic kidney disease.
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There are several potential explanations for the inconsis-
tent MR findings across these studies. Yu et al. used ge-
netic associations for blood pressure that were adjusted for
BMI with genetic associations for eGFR and CKD that
were not adjusted for BMI in their MR analysis. Given the
causal role of BMI on both CKD and hypertension, only
controlling for BMI in the exposure data may create unin-
tended bias in the MR estimates, as described previously.51
An alternative explanation is the difference in CKD case
ascertainment. Specifically, we used CKD cases that were
clinically diagnosed, which may bring additional statistical
power and provide more reliable evidence for the effect of
blood pressure on CKD.
Given the difference in MR evidence across the ances-
tries that we observed, combined with previous evidence
from the literature, it is possible that hypertension could
have differential effects on CKD by ancestry. Ethnic dis-
parities in relation to hypertension and CKD have previ-
ously been reported.52,53 For example, Chinese people
with hypertension have a lower risk of CKD compared
with European people with hypertension.52 Additionally,
in 2019, hypertensive nephropathy accounted for 27% of
the overall CKD cases in the USA but 20.8% of the overall
CKD cases among Chinese.54,55 Further well-powered
studies are needed to validate the causal effect of blood
pressure on CKD across ancestries.
In addition, our MR analyses suggested substantial
causal effects for BMI and nephrolithiasis on CKD.
Previous observational studies have suggested that BMI is
positively associated with CKD onset56 and end-stage renal
disease57,58 and negatively associated with kidney func-
tion.59 The effect of weight loss on reducing the risk of dia-
betic nephropathy in patients with T2D60 and slowing
kidney-function decline have also been reported.61 Using
linear and non-linear MR approaches, we observed a
threshold causal relationship between BMI and CKD.
Moreover, nephrolithiasis is a common and serious health
concern globally.62–64 There is increasing evidence to sug-
gest that having kidney stones is a risk factor for CKD.62,65
For instance, people with kidney stones tend to have lower
eGFR.63,66 A previous cohort study suggested that even a
single kidney-stone episode was associated with an in-
creased likelihood of adverse renal outcomes.67 A recent
genetic study also suggested an inverse association between
eGFR and kidney-stone formation.68 However, the causal
relationship between nephrolithiasis and CKD had not
been investigated previously. Our MR analysis supported
the causal effect of increased nephrolithiasis risk on in-
creasing CKD risk. This is of particular importance as ob-
structive nephropathy is among the leading causes of CKD
in the general population. Specifically, it is the third lead-
ing cause of CKD among the Chinese population and has
been estimated to be present in 15.6% of CKD cases.55
Notably, diabetic kidney disease is considered the most
common type of CKD worldwide.69 A previous MR study
of T2D on CKD in Chinese participants suggested a strong
causal link between the two phenotypes,70 which aligned
with our MR findings in both East Asians and Europeans.
However, despite the reliable evidence for a causal effect
of T2D on CKD, our linear and non-linear MR found
Table 1 Systematic evaluation of Mendelian-randomization evidence with existing clinical evidence
Risk factors Clinical evidence MR evidence Clinical implications
in KDIGO guideline from this study
Blood pressure Established Strong evidence in Europeans Suggest different prevention strategy for
CKD across ancestriesWeak evidence in East Asians
BMI Emerging Strong in both ancestries Suggest optimal control level of BMI
as 25
Nephrolithiasis Emerging Strong in both ancestries Suggest assessment of kidney stones in
high-risk groups
Diabetic phenotypes Established Strong for diabetes but weak evidence for
other glycaemic traits
Imply glucose-independent effect of
diabetes on CKD
Lipid phenotypes Established Strong evidence for HDL-C, cholesteryl
ester transfer protein (CETP) and Lp(a)
Suggest cholesteryl ester transfer protein
(CETP) and Lp(a) inhibition as inter-
vention targets for CKD prevention
Low sleep duration Emerging Strong evidence in one study but lack of
replication in other studies
Suggest future studies to confirm the
effect of sleeping on CKD
Smoking, uric acid, CRP, bone,
metal, vitamin, thyroid
phenotypes
Emerging Little evidence –
CKD, chronic kidney disease; BMI, body mass index; HDL, high-density lipoprotein; CETP, cholesteryl ester transfer protein; Lp(a), lipoprotein (a); CRP,
C-reactive protein.
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limited evidence to support the causal effects of glucose-
and insulin-related phenotypes on CKD. This is consistent
with the findings from a previous MR study conducted in
Europeans.71 It has also been observed that with increasing
use of glucose-lowering medications, the prevalence of
CKD in diabetics has not reduced as much as expected.72
This is supported by a meta-analysis of RCTs that found
intensive glucose control to have an inconclusive effect on
reducing the risk of end-stage renal disease.73 These find-
ings, together with our MR results, suggest that glucose-
independent pathways could play a role in the relationship
between diabetes and CKD. Furthermore, it has consis-
tently been suggested that the beneficial effects of SGLT2
inhibitors (antidiabetic medication) on renal outcomes
may be mediated by glucose-independent pathways.74,75
One potential limitation of our analysis in relation to inter-
rogating this finding is that the glucose GWAS that we
used was conducted in a general population whose fasting
glucose levels are <7 mmol/L. Existing MR studies using
these data have made the assumption that the glucose
change in the general population is similar to that in dia-
betic patients (i.e. individuals whose fasting glucose levels
are typically >7 mmol/L), which may not necessarily be
true. Although our stratified MR analysis showed little dif-
ference between diabetic and non-diabetic patients, we be-
lieve that better genetic instruments derived from a
diabetic patient population and well-designed clinical trials
are needed to evaluate the effect of glucose-dependent and
-independent mechanisms on CKD prevention.
Hyperlipidaemia and dyslipidaemia have been widely
documented to be associated with kidney disease.76,77 But
the causal effects of lipid components on CKD are still
unclear. A few recent MR studies have suggested a protec-
tive effect of higher HDL-C on CKD in Europeans,78 an
adverse effect of higher triglycerides on CKD in Chinese79
and a nominal effect of lipoprotein(a) lowering on reduc-
ing CKD risk.80 In this study, we validated the HDL-C
findings, confirmed the triglycerides effect in Biobank
Japan and strengthened the evidence of the lipoprotein(a)
finding in completely independent samples. Besides con-
firming these existing findings, our study also established
novel causal evidence for the apolipoprotein A-I and non-
apolipoprotein A-I properties of HDL-C on CKD risk in
Europeans. Furthermore, our study extended the findings
from recent studies of HDL-C81 and cholesteryl ester trans-
fer protein inhibitors,82 which support the causal effect of
circulating cholesteryl ester transfer protein levels on CKD
in Europeans. The observed causal effect of HDL-C and
the effect of cholesteryl ester transfer protein levels on
CKD raises the possibility that increasing the HDL-C con-
centration may offer a potential intervention strategy for
CKD prevention. Moreover, our study demonstrated that
the causal effect of lipoprotein(a) levels on CKD was inde-
pendent of the apolipoprotein(a) size. This finding, to-
gether with previous observational evidence,83–85 implies
the possibility of lipoprotein(a)-reduction therapies, such
as Pelacarsen [also known as IONIS-APO(a)-LRx], on re-
ducing CKD risk.86 Overall, our findings have highlighted
the potential for several lipid-management strategies in re-
ducing CKD risk.
Strengths and limitations
Our study has some strengths compared with previous
studies in this setting. We used clinically diagnosed CKD
(instead of only using eGFR<60 ml/min/1.73 m2 to define
CKD) in two European (UK Biobank and HUNT) and two
East Asian (China Kadoorie Biobank and Japan-Kidney-
Biobank/ToMMo) studies. These four studies included
participants with abnormal urine protein levels but with
normal eGFR as CKD cases. This increased the robustness
of the CKD definition. By comprehensively validating the
MR findings in the six CKD studies, we also greatly en-
hanced the reliability of the causal atlas that we derived of
risk factors for CKD.
Our study also has some potential limitations. First, we
used the ICD 10 code to define CKD cases in three of the
six studies. Such selection criteria excluded undiagnosed
cases and diagnoses made in an outpatient setting.
Considering the low disease awareness of CKD,87,88 such
misclassification of the outcome may reduce the power of
our study. However, as a trade-off, such an approach also
excluded non-CKD samples from the case group (e.g. par-
ticipants with a single eGFR measurement of <60 due to
measurement error), which brought additional power to
the statistical analysis. Second, we set up a stringent
Bonferroni-corrected threshold together with other criteria
(e.g. little evidence of pleiotropy) to select the top MR find-
ings. Such a strategy could create some false-negative find-
ings but minimize the possibility of identifying false-
positive findings. With the aim of supporting the future
clinical practice of CKD management, we decided to apply
such a stringent strategy to provide the most reliable causal
evidence using genetics. Second, in the MR analysis, ge-
netic predictors for binary exposures (e.g. coronary artery
disease) are not mimicking the exposure itself, but the pre-
disposition to the exposure instead.89 Consequently, our
results must be interpreted as the effect of removing the
predisposition to the binary exposure (rather than treat-
ment of the exposure) to reduce CKD risk. In addition, due
to the relative lack of GWAS samples in East Asians, we
could only examine causal effects for 17 of the 45 risk fac-
tors for this ancestry. For the same reason, the number of
instruments for each risk factor in the analyses differed
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between the two ancestries. For risk factors with different
MR evidence across ancestries, we conducted a compre-
hensive set of sensitivity analyses to minimize the influence
of differences in power and instrument strength across
ancestries. Other limitations of the study are listed in
Supplementary Note S7 (available as Supplementary data
at IJE online).
Conclusions
By evaluating the causal evidence for 45 risk factors on
CKD in >1 million individuals of European ancestry and
17 risk factors in >250 000 individuals of East Asian an-
cestry, we have shown that eight risk factors are reliably
causal for CKD in Europeans and three of these are also
causal in East Asians. These risk factors are predominantly
related to cardiometabolic health, which supports the
shared causal link between cardiometabolic health and
kidney function. The different causal pattern between hy-
pertension and CKD in Europeans compared with that in
East Asians suggests that blood pressure might have an
ancestry-specific role in CKD aetiology. Ultimately, our
findings may have important clinical implications in terms
of informing primary prevention in ‘at-risk’ individuals
with normal renal function, which may in turn help to re-
duce the burden of CKD globally.
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Supplementary data are available at IJE online.
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